Estradiol patch shortages: what's real, what's overstated

What did @thehrtclub actually say?

The creator argues the estrogen patch shortage is a systemic failure, not just a demand problem. They claim HRT use dropped from 40% of menopausal women before 2002 to 1.8% by 2024, then rebounded to about 5%. They also point to pharmacy benefit managers (PBMs) owned by insurance companies as a key reason low-margin generics like estradiol patches stay unreliable. The framing is structural: a system that never incentivized consistent supply of a cheap, decades-old drug.

This is a more substantive argument than most TikTok hormone content. The creator is summarizing a reported op-ed from the LA Times by Jennifer Weiss-Wolf and Dr. Suzanne Gilberg-Lenz, and they mostly do it accurately. But some numbers deserve a closer look.

Does the science back this up?

The broad strokes are accurate. The 2002 Women's Health Initiative (WHI) study did trigger a dramatic drop in HRT prescribing. But the specific figures the creator cites need context, and one of them is off.

The 40% pre-2002 figure is in the right ballpark. A widely cited analysis by Hersh, Stefanick, and Stafford published in JAMA in 2004 documented that HRT use peaked around 2001 and fell sharply after the WHI findings were released in July 2002. Estimates of peak use vary between 33% and 42% depending on the population studied, so 40% is defensible.

The 1.8% figure is where things get murky. The creator says "by 2024, only 1.8% of women were on HRT." That number likely reflects a specific dataset, possibly prescription fill data rather than prevalence across all menopausal women, or it may refer to a narrow age or demographic slice. A 2023 analysis in Menopause journal (Rozenberg et al.) put current U.S. HRT use closer to 3-5% of eligible women. The 1.8% number is not fabricated, but presenting it as the definitive 2024 figure without sourcing is sloppy.

On PBMs: the claim that the three dominant PBMs are owned by insurance conglomerates is accurate. CVS Caremark (Aetna), Express Scripts (Cigna), and OptumRx (UnitedHealth) together process roughly 80% of U.S. prescription claims, per the American Medical Association's 2023 PBM reform brief.

What did they get wrong (or right)?

They got the structural argument right. Estradiol patches are off-patent, cheap, and have thin margins. That genuinely creates weak incentives for manufacturers and distributors to maintain robust supply chains. The FDA's drug shortage database has listed estradiol patches at various points, which supports the creator's core point.

What they got imprecise: the 1.8% figure. The creator presents it as a clean data point without attribution. If that number comes from a specific claims database or a narrow study population, saying it represents all menopausal women in 2024 overstates the precision. The jump from 1.8% to 5% also implies faster recent growth than most published data supports. The rebound in HRT interest is real, but the pace varies by source.

They also slightly mispronounce the author's name ("Gilbert-Glens" instead of Gilberg-Lenz), which is minor but worth noting since they're citing a specific expert's credibility.

• Accurate: 40% pre-2002 HRT use, WHI-driven decline, PBM market concentration
• Imprecise: 1.8% figure lacks sourcing and may not represent the full menopausal population
• Accurate directionally: low-margin generics face weaker supply chain investment

What should you actually know?

The estrogen patch shortage is documented and real. The FDA's shortage list and independent pharmacy reports from 2022 to 2024 confirm supply inconsistency for multiple estradiol patch formulations. This is not a conspiracy framing; it reflects actual market dynamics around low-margin generic drugs.

HRT is not appropriate for everyone. Women with a personal history of certain hormone-sensitive cancers, prior blood clots, or specific cardiovascular conditions need individualized clinical evaluation before starting any hormone therapy. The creator is not prescribing, but their audience should know that "patches are in stock" is not the same as "patches are right for you."

The WHI study that triggered the 2002 warnings has since been substantially reanalyzed. The 2017 reanalysis by Manson et al. in JAMA and ongoing work from the Menopause Society suggest the original risk framing was applied too broadly, particularly to younger, recently menopausal women. Context matters enormously here.

If you are looking for HRT and your pharmacy has stock issues, that is a legitimate problem worth solving. Work with a licensed clinician to evaluate your options, including different delivery methods, not just patches.